GenPath logo in conjunction with urology

Hereditary Prostate Cancer

Testing with the Hereditary Prostate Cancer Panel may be appropriate if your patient and/or the family history is suggestive of a hereditary predisposition to prostate cancer. This includes:

  • Prostate cancer diagnosed at an early age (i.e. <60 years)
  • Metastatic/aggressive prostate cancer
  • Prior tumor testing that indicated an increased risk for a hereditary cancer syndrome (i.e. variant identified on tumor sequencing and/or abnormal MSI/IHC)
  • An individual patient with multiple cancers (such as prostate and pancreatic cancer)
  • Multiple relatives diagnosed with prostate cancer (especially aggressive; Gleason score ≥ 7) and/or related cancers (breast, ovarian, pancreatic, colon, etc.) on the same side of the family

The panel consists of 16 genes associated with an increased risk for prostate and other cancers. Genes tested for in this panel include: ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53.

Test CodeTest Name
J665-1Hereditary Prostate Cancer Panel
©2019 GenPath, a division of BioReference Laboratories Inc., an OPKO Health Company